Skip to content

Effectiveness of Ivermectin on Outpatient Treatment of Covid-19 Patients

Investigation of the Effectiveness of Ivermectin on Outpatient Treatment of Covid-19 Patients, Shiraz City, Southern Iran, 2020: A Randomized Controlled Trial Study (RCT)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210213050344N1
Enrollment
375
Registered
2021-04-06
Start date
2021-04-10
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19 disease. Covid-19

Interventions

Intervention 1: Intervention group 1: As a single dose, receive 4 tablets of Ivermectin 3 mg on the first day of treatment. M.A. Holder: Jam Tadbir Kala / Tehran, Iran - Manufactured by: Europhartec /

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Clients to selected outpatient treatment centers in Shiraz Only mild symptoms and clinical manifestations (including: fever less than 38 degrees, sore throat with or without dry cough, chills, headache, loss of taste and smell, nausea, vomiting, anorexia, diarrhea, body aches, weakness and Excessive fatigue, persistent yard symptoms) Positive RT-PCR test result Age between 18 and 80 years People with underlying disease (to evaluate the effectiveness of the drug on people with underlying disease) Individuals who have completed and signed the written consent to participate in the project Blood oxygen level 93% and above (O2 sat = 93%)

Exclusion criteria

Exclusion criteria: Pregnant mothers Breastfeeding mothers Severe liver disease Severe kidney disease Severe lung disease HIV Positive patients Chronic obstructive pulmonary disease (COPD) Participate in another RCT Dissatisfaction with participating in the study

Design outcomes

Primary

MeasureTime frame
The trend of clinical symptoms of Covid-19 disease. Timepoint: Seven time periods on days: Zero, 1, 3, 7, 14, 21 and 28. Method of measurement: Clinical information by completing a qualitative questionnaire and conduct interviews and observations.;Blood oxygen level (O2 Saturation). Timepoint: Seven Time Periods on Days: Zero, 1, 3, 7, 14, 21 and 28. Method of measurement: Pulse oximeter device.;Hospitalization. Timepoint: Seven time periods on days: Zero, 1, 3, 7, 14, 21 and 28. Method of measurement: Clinical information by completing a qualitative questionnaire and observation.;Requires intubation or ICU. Timepoint: Seven time periods on days: Zero, 1, 3, 7, 14, 21 and 28. Method of measurement: Clinical information by completing a qualitative questionnaire and observation.;Death. Timepoint: Seven time periods on days: Zero, 1, 3, 7, 14, 21 and 28. Method of measurement: Clinical information by completing a qualitative questionnaire and observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Semati

Shiraz University of Medical Sciences

semati.epid77@gmail.com+98 71 3212 2368

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026